Lippincott Williams & Wilkins



Supplementary Material

Search Strategy

May 11, 2016

MEDLINE

1. Exp eosinophilic esophagitis/

2. Eosinophilic esophagitis.mp.

3. Eosinophilic oesophagitis.mp.

4. Allergic eosophagitis.mp.

5. EOE.mp.

6. Or/1-5

EMBASE

1. Exp eosinophilic esophagitis/

2. Eosinophilic esophagitis.mp.

3. Eosinophilic oesophagitis.mp.

4. Allergic eosophagitis.mp.

5. EOE.mp.

6. Or/1-5

Cochrane CENTRAL

#1 MeSH descriptor: [Eosinophilic Esophagitis] explode all trees

#2 Eosinophilic esophagitis.mp.

#3 Eosinophilic oesophagitis.mp.

#4 Allergic eosophagitis.mp.

#5 EOE.mp.

#6 #1 or #2 or #3 or #4 or #5

7. Or/1-5

8. Diagnos*.mp.

9. Assess*.mp.

10. Evalu*.mp.

11. Sever*.mp.

12. Test*.mp.

13. Endosc*.mp.

14. Biop*.mp.

15. Cytosponge.mp.

16. Gene polymerase chain reaction.mp.

17. PCR.mp.

18. Barium.mp.

19. Biomark*.mp.

20. Score*.mp.

21. Scorin*.mp.

22. Scale*.mp.

23. Scalin*.mp.

24. Index*.mp.

25. Indic*.mp.

26. Grade*.mp.

27. Grad*.mp.

28. Classif*.mp.

29. Or/7-27

30. 6 and 28

Complete list of references corresponding to studies meeting eligibility criteria (N=130)

1. Abu-Sultaneh SM, Durst P, Maynard V, Elitsur Y. Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis. Digestive Diseases & Sciences. 2011;56(1):97-102.

2. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. American Journal of Gastroenterology. 2007;102(10):2271-9.

3. Aceves SS, Newbury RO, Chen D, Mueller J, Dohil R, Hoffman H, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy. 2010;65(1):109-16.

4. Aceves SS, Newbury RO, Dohil MA, Bastian JF, Dohil R. A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. Annals of Allergy, Asthma, & Immunology. 2009;103(5):401-6.

5. Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clinical Gastroenterology & Hepatology. 2012;10(7):742-9.e1.

6. Al-Hussaini A, Al-Idressi E, Al-Zahrani M. The role of allergy evaluation in children with eosinophilic esophagitis. Journal of Gastroenterology. 2013;48(11):1205-12.

7. Andreae DA, Hanna MG, Magid M, Bagiella E, Malerba S, Chehade M. Swallowed fluticasone is an effective and safe long-term maintenance therapy in children with eosinophilic esophagitis. Gastroenterology. 2015;1):S30.

8. Arbizu R, Crissinger K. Correlation among clinical symptoms, endoscopic findings, and histopathologic findings in pediatric patients with eosinophilic esophagitis. Journal of Investigative Medicine. 2011;59 (2):513.

9. Arias A, Lucendo AJ, Martinez-Fernandez P, Gonzalez-Castro AM, Fortea M, Gonzalez-Cervera J, et al. Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis. Clinical & Experimental Allergy. 2016;46(1):78-91.

10. Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011; 141(5):[1593-604 pp.].

11. Attwood SEA, Lewis CJ, Bronder CS, Morris CD, Armstrong GR, Whittam J. Eosinophilic oesophagitis: A novel treatment using Montelukast. Gut. 2003;52(2):181-5.

12. Bedell A, Taft TH, Keefer L, Pandolfino J. Development of the Northwestern Esophageal Quality of Life Scale: A Hybrid Measure for Use Across Esophageal Conditions. Am J Gastroenterol. 2016;111(4):493-9.

13. Beppu L, Yang T, Luk M, Newbury RO, Palmquist J, Dohil R, et al. MMPs-2 and -14 Are Elevated in Eosinophilic Esophagitis and Reduced Following Topical Corticosteroid Therapy. Journal of Pediatric Gastroenterology & Nutrition. 2015;61(2):194-9.

14. Bergquist H, Larsson H, Johansson L, Bove M. Mometasone furoate in patients with eosinophilic esophagitis. Otolaryngology - Head and Neck Surgery. 2011;145:81-2.

15. Bohm M, Richter JE, Kelsen S, Thomas R. Esophageal dilation: simple and effective treatment for adults with eosinophilic esophagitis and esophageal rings and narrowing. Diseases of the Esophagus. 2010;23(5):377-85.

16. Butz BK, Wen T, Gleich GJ, Furuta GT, Spergel J, King E, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014;147(2):324-33.e5.

17. Chhabra A, Matsui EC, Wood RA. Clinical and histopathologic response to various treatment interventions in patients with EE. Journal of Allergy and Clinical Immunology. 2009;1):S247.

18. Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147(3):602-9.

19. Collins MH, Alexander ES, Martin LJ, Rothenberg ME. Eosinophilic esophagitis (EOE) histologic changes more strongly associate with treatment status than peak eosinophil count (PEC). Journal of Allergy and Clinical Immunology. 2015;1):AB39.

20. Collins MH, Martin LJ, Alexander ES, Pentiuk S, Ellison A, Putnam PE, et al. Histology scoring system (HSS) is superior to peak eosinophil count (PEC) to identify treated vs untreated eosinophilic esophagitis (EOE) patients. Journal of Allergy and Clinical Immunology. 2012;1):AB96.

21. Colson D, Kalach N, Soulaines P, Vannerom Y, Campeotto F, Talbotec C, et al. The impact of dietary therapy on clinical and biologic parameters of pediatric patients with eosinophilic esophagitis. The Journal of Allergy & Clinical Immunology in Practice. 2014;2(5):587-93.

22. Croft NM. Biologicals Move Into the Esophagus. Gastroenterology. 2007;133(1):358-60.

23. Dellon ES, Cotton CC, Gebhart JH, Higgins LL, Beitia R, Woosley JT, et al. Accuracy of the Eosinophilic Esophagitis Endoscopic Reference Score in Diagnosis and Determining Response to Treatment. Clinical Gastroenterology & Hepatology. 2016;14(1):31-9.

24. Dellon ES, Gebhart JH, Higgins LL, Hathorn KE, Woosley JT, Shaheen NJ. The esophageal biopsy "pull" sign: a highly specific and treatment-responsive endoscopic finding in eosinophilic esophagitis. Gastrointestinal Endoscopy. 2016;83(1):92-100.

25. Dellon ES, Gibbs WB, Fritchie KJ, Rubinas TC, Wilson LA, Woosley JT, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clinical Gastroenterology & Hepatology. 2009;7(12):1305-13.

26. Dellon ES, Gibbs WB, Rubinas TC, Fritchie KJ, Madanick RD, Woosley JT, et al. Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Gastrointestinal Endoscopy. 2010;71(4):706-12.

27. Dellon ES, Irani AM, Hill MR, Hirano I. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Alimentary Pharmacology & Therapeutics. 2013;38(6):634-42.

28. Dellon ES, Katzka DA, Collins MH, Hamdani M, Gupta SK, Hirano I, et al. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. Gastroenterology. 2017;152(4):776-86 e5.

29. Dellon ES, Rusin S, Gebhart JH, Covey S, Higgins LL, Beitia R, et al. Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study. American Journal of Gastroenterology. 2015;110(6):821-7.

30. Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 2012;143(2):321-4 e1.

31. Dellon ES, Woodward K, Speck O, Hores J, Woosley JT, Shaheen NJ. Symptoms do not correlate with histologic response in eosinophilic esophagitis. Gastroenterology. 2012;1):S432.

32. Denning KL, Al-Subu A, Elitsur Y. Immunoreactivity of p53 and Ki-67 for dysplastic changes in children with eosinophilic esophagitis. Pediatric & Developmental Pathology. 2013;16(5):331-6.

33. Dilger K, Lopez-Lazaro L, Marx C, Bussmann C, Straumann A. Biotransformation of budesonide via cytochrome P450 3A enzymes in active eosinophilic esophagitis. Swiss Medical Weekly. 2012;142:2S.

34. Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology. 2010; 139(2):[418-29 pp.].

00000aacb35e&acdnat=1481118759_b7d9c124001e8a02330018c3d0f1c3ca.

35. Erwin EA, Kruszewski P, Russo J, Workman LJ, Platts-Mills TAE. Serum IgE levels and response to cow's milk elimination diet in patients with eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2015;1):AB43.

36. Flood EM, Beusterien KM, Amonkar MM, Jurgensen CH, Dewit OE, Kahl LP, et al. Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires. Current Medical Research & Opinion. 2008;24(12):3369-81.

37. Franciosi JP, Hommel KA, Bendo CB, King EC, Collins MH, Eby MD, et al. PedsQL eosinophilic esophagitis module: feasibility, reliability, and validity. Journal of Pediatric Gastroenterology & Nutrition. 2013;57(1):57-66.

38. Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterology. 2011;11:126.

39. Francis DL, Foxx-Orenstein A, Arora AS, Smyrk TC, Jensen K, Nord SL, et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis. Alimentary Pharmacology & Therapeutics. 2012;35(2):300-7.

40. Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013;62(10):1395-405.

41. Garrean CP, Patil D, Gonsalves N, Yang GY, Hirano I. Comparison of endoscopic and histologic response in patients with eosinophilic esophagitis treated with proton pump inhibition, topical fluticasone, and dietary elimination. Gastroenterology. 2009;1):A279.

42. Ghaffari G. A randomized double blind placebo controlled crossover study of the effect of swallowed beclomethasone dipropionate on inflammatory markers in adult patients with eosinophilic esophagitis:A pilot study. Annals of Allergy, Asthma and Immunology. 2012; 109.

43. Gil-Simon P, Armentia A, Vargas AL, Armentia BM, Rubiales BM, Sanchez-Ocana R, et al. Efficacy of immunotherapy and alergen-molecular-study-led diet treatments in eosinophilic esophagitis. Gastroenterology. 2014;1):S-667.

44. Gomez-Torrijos E, Garcia-Rodriguez R, Castro-Jimenez A, Rodriguez-Sanchez J, Mendez Diaz Y, Molina-Infante J. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Alimentary Pharmacology & Therapeutics. 2016;43(4):534-40.

45. Gonsalves N, Doerfler B, Schwartz S, Yang GY, Zalewski A, Amsden K, et al. Prospective trial of four food elimination diet demonstrates comparable effectiveness in the treatment of adult and pediatric eosinophilic esophagitis. Gastroenterology. 2013;1):S154.

46. Gonsalves N, Hirano I. Quality of life assessment in adults with EoE at baseline and after treatment with dietary therapy: Is the treatment worse than the disease? Gastroenterology. 2009;1):A137.

47. Gonsalves N, Schroeder H, Doerfler B, Hirano I, Bryce P. A unique gene expression profile may predict responsiveness to dietary elimination with six food elimination diet in adults with eosinophilic esophagitis. Gastroenterology. 2012;1):S181.

48. Gonsalves N, Yang GY, Doerfler B, Ritz S, Ditto AM, Hirano I. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology. 2012;142(7):1451-9.e1.

49. Gupta S, Kita H, Collins M, Perschy T, Heath A, Jurgensen C. Utility of eosinophil-derived neurotoxin as a biomarker in eosinophilic esophagitis: results from a randomized, double-blind, controlled trial of mepolizumab in pediatric patients. Journal of Allergy and Clinical Immunology. 2010;1):AB234.

50. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clinical Gastroenterology & Hepatology. 2015;13(1):66-76.e3.

51. Helou EF, Simonson J, Arora AS. 3-Yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults. American Journal of Gastroenterology. 2008;103(9):2194-9.

52. Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. Journal of Allergy & Clinical Immunology. 2012;129(6):1570-8.

53. Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489-95.

54. Hsu Blatman KS, Gonsalves N, Hirano I, Bryce PJ. Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy. Journal of Allergy & Clinical Immunology. 2011;127(5):1307-8.e3.

55. Hudgens S, Evans C, Philips E, Hill M. Psychometric validation of the dysphagia symptom questionnaire in eosinophilic esophagitis patients treated with oral budesonide suspension. Value in Health. 2015;18 (3):A226.

56. Iuliano S, Fugazza A, Manzali E, Lapetina I, Ghiselli A, De'Angelis GL. Eosinophilic esophagitis and ECP: Which correlation? Digestive and Liver Disease. 2013;45:e287-e8.

57. Jawa H, Chande N. Dilation treatment in eosinophilic esophagitis. Canadian Journal of Gastroenterology Conference: Canadian Digestive Diseases Week. 2009;23.

58. Kagalwalla A, Amsden K, Makhija MM, Wechsler JB, Olive A, Schwartz S, et al. A multicenter study assessing the clinical, endoscopic and histologic response to four food elimination diet for the treatment of eosinophilic esophagitis. Gastroenterology. 2015;1):S30.

59. Kagalwalla AF, Amsden K, Shah A, Ritz S, Manuel-Rubio M, Dunne K, et al. Cow's milk elimination: a novel dietary approach to treat eosinophilic esophagitis. Journal of Pediatric Gastroenterology & Nutrition. 2012;55(6):711-6.

60. Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clinical Gastroenterology & Hepatology. 2006;4(9):1097-102.

61. Katzka DA, Geno DM, Ravi A, Smyrk TC, Lao-Sirieix P, Miremadi A, et al. Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis.[Erratum appears in Clin Gastroenterol Hepatol. 2015 Aug;13(8):1552 Note: Miramedi, Ahmed [corrected to Miremadi, Ahmed]]. Clinical Gastroenterology & Hepatology. 2015;13(1):77-83.e2.

62. Kavitt RT, Ates F, Slaughter JC, Higginbotham T, Vaezi MF. Dilate or medicate? A randomized, blinded, controlled trial comparing esophageal dilation to no dilation among adult patients with eosinophilic esophagitis. Gastroenterology. 2014; 146(5 suppl. 1)

63. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503-12.

64. Kern E, Taft T, Zalewski A, Hirano I. Quality of life considerations in adult patients with eosinophilic esophagitis. Gastroenterology. 2014;1):S672-S3.

65. Kia L, Matthew N, Zalewski A, Carlson DA, Nirmala G, Straumann A, et al. Oral fluticasone powder improves histopathology in adults with eosinophilic esophagitis. American Journal of Gastroenterology. 2015;110:S724-S5.

66. Klinnert MD, Silveira L, Harris R, Moore W, Atkins D, Fleischer DM, et al. Health-related quality of life over time in children with eosinophilic esophagitis and their families. Journal of Pediatric Gastroenterology & Nutrition. 2014;59(3):308-16.

67. Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology. 2006;131(5):1381-91.

68. Kruszewski P, Russo JM, Erwin EA. Outcomes in pediatric eosinophilic esophagitis treated with cow's milk elimination versus fluticasone. Gastroenterology. 2014;1):S-761.

69. Lai J, Levine J. Conservative long-term treatment of children with eosinophilic esophagitis. Journal of Pediatric Gastroenterology and Nutrition. 2010;51:E17-E8.

70. Larsson H, Bergman K, Finizia C, Johansson L, Bove M, Bergquist H. Dysphagia and health-related quality of life in patients with eosinophilic esophagitis: a long-term follow-up. European Archives of Oto-Rhino-Laryngology. 2015;272(12):3833-9.

71. Lee J, Huprich J, Kujath C, Ravi K, Enders F, Smyrk TC, et al. Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy. Clinical Gastroenterology & Hepatology. 2012;10(5):481-6.

72. Leung J, Mehrzad R, Hundal NV, Alejos A, Hesterberg PE, Katz AJ, et al. Longitudinal Perspective on Managing Refractory Eosinophilic Esophagitis. The Journal of Allergy & Clinical Immunology in Practice. 2015;3(6):951-6.

73. Leung J, Nguyen-Traxler A, Lee EM, Yip JS, Weinstock JV, Chan WW, et al. Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis. Allergy & Asthma Proceedings. 2012;33(6):519-24.

74. Levine J, Lai J, Edelman M, Schuval SJ. Conservative long-term treatment of children with eosinophilic esophagitis. Annals of Allergy, Asthma, & Immunology. 2012;108(5):363-6.

75. Liacouras CA, Wenner WJ, Brown K, Ruchelli E. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. Journal of Pediatric Gastroenterology & Nutrition. 1998;26(4):380-5.

76. Lieberman JA, Morotti RA, Konstantinou GN, Yershov O, Chehade M. Dietary therapy can reverse esophageal subepithelial fibrosis in patients with eosinophilic esophagitis: a historical cohort. Allergy. 2012;67(10):1299-307.

77. Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, et al. A pilot study of omalizumab in eosinophilic esophagitis. PLoS ONE 2015;10(3):e0113483.

78. Lucendo AJ, Arias Á, González-Cervera J, Yagüe-Compadre JL, Guagnozzi D, Angueira T, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. The Journal of allergy and clinical immunology. 2013; 131(3):[797-804 pp.].

79. Lucendo AJ, De Rezende LC, Jimenez-Contreras S, Yague-Compadre JL, Gonzalez-Cervera J, Mota-Huertas T, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Digestive Diseases & Sciences. 2011;56(12):3551-8.

80. Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. American Journal of Gastroenterology. 2003;98(4):777-82.

81. Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2016;65(3):390-9.

82. Moawad FJ, Veerappan GR, Dias JA, Baker TP, Maydonovitch CL, Wong RKH. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. American Journal of Gastroenterology. 2013;108(3):366-72.

83. Molina-Infante J, Arias A, Barrio J, Rodriguez-Sanchez J, Sanchez-Cazalilla M, Lucendo AJ. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. Journal of Allergy & Clinical Immunology. 2014;134(5):1093-9.e1.

84. Moy N, Heckman MG, Gonsalves N, Achem SR, Hirano I. Inter-observer agreement on endoscopic esophageal findings in eosinophilic esophagitis (EoE). Gastroenterology. 2011;1):S236.

85. Muir RJ, Ee LC, Lewindon PJ, Withers GD. Food allergen restricted diet in the treatment of paediatric eosinophilic oesophagitis. Journal of Pediatric Gastroenterology and Nutrition. 2010;50:E136.

86. Nennstiel S, Bajbouj M, Becker V, Slotta-Huspenina J, Wagenpfeil S, Schmid RM, et al. High-resolution manometry in patients with eosinophilic esophagitis under topical steroid therapy-a prospective observational study (HIMEOS-study). Neurogastroenterology & Motility. 2016;28(4):599-607.

87. Nicodeme F, Hirano I, Chen J, Robinson K, Lin Z, Xiao Y, et al. Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clinical Gastroenterology & Hepatology. 2013;11(9):1101-7.e1.

88. Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R, et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. Journal of Allergy & Clinical Immunology. 2013;131(6):1576-82.

89. Page SL, Menown K, Daniel J, Friesen C. Montelukast as maintenance treatment of eosinophilic esophagitis. Journal of Pediatric Gastroenterology and Nutrition. 2010;51:E21.

90. Peterson KA, Byrne KR, Vinson LA, Ying J, Boynton KK, Fang JC, et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. American Journal of Gastroenterology. 2013;108(5):759-66.

91. Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Digestive Diseases & Sciences. 2010;55(5):1313-9.

92. Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. Alimentary Pharmacology & Therapeutics. 2016;43(9):985-93.

93. Remedios C, Garcia C, Gomez E, Garcia R, De La Roca F, Rodriguez J, et al. Eosinophilic esophagitis: A possible long term complication of immunotherapy for cow's milk allergy. Allergy: European Journal of Allergy and Clinical Immunology. 2014;69:428.

94. Rhijn BD, Verheij J, Bergh Weerman MA, Verseijden C, Wijngaard RM, Jonge WJ, et al. Histological Response to Fluticasone Propionate in Patients With Eosinophilic Esophagitis Is Associated With Improved Functional Esophageal Mucosal Integrity. The American journal of gastroenterology. 2015; 110(9):[1289-97 pp.].

95. Rodrigues M, D'Amico MFM, Patino FRA, Barbieri D, Damiao AOMC, Sipahy AM. Clinical manifestations, treatment, and outcomes of children and adolescents with eosinophilic esophagitis. Jornal de Pediatria. 2013;89(2):197-203.

96. Rodriguez-Sanchez J, Gomez Torrijos E, Lopez Viedma B, de la Santa Belda E, Martin Davila F, Garcia Rodriguez C, et al. Efficacy of IgE-targeted vs empiric six-food elimination diets for adult eosinophilic oesophagitis. Allergy. 2014;69(7):936-42.

97. Rodriguez-Sanchez J, Gomez-Torrijos E, de-la Santa-Belda E, Lopez-Viedma B, Martin-Davila F, Pilkington-Woll JP, et al. Effectiveness of serological markers of eosinophil activity in monitoring eosinophilic esophagitis. Revista Espanola de Enfermedades Digestivas. 2013;105(8):462-7.

98. Rodriguez-Sanchez J, Molina-Infante J, Barrio J, Perez-Martinez I, Rubiales BM. Correlation of clinical and endoscopic eosinophilic esophagitis activity with histological remission. Gastroenterology. 2014;1):S-667.

99. Rodriguez-Sanchez J, Rojo MG, Viedma BL, de la Santa Belda E, Palomar PO, Torrijos EG, et al. Accuracy of liquid cytology in the diagnosis and monitoring of eosinophilic oesophagitis. United European Gastroenterology Journal. 2014;2(6):475-81.

100. Rodriguez-Sanchez J, Torrijos EG, Escobedo RM, Davila FM, Viedma BL, Alconada CR, et al. VAS-EoE score: A new symptoms-assessment tool for eosinophilic esophagitis. Gastroenterology. 2013;1):S492-S3.

101. Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. Journal of Allergy & Clinical Immunology. 2015;135(2):500-7.

102. Safroneeva E, Coslovsky M, Kuehni CE, Zwahlen M, Haas NA, Panczak R, et al. Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Alimentary Pharmacology & Therapeutics. 2015;42(8):1000-10.

103. Schaefer ET, Fitzgerald JF, Molleston JP, Croffie JM, Pfefferkorn MD, Corkins MR, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2008; 6(2):[165-73 pp.].

104. Schoepfer A, Portmann S, Safroneeva E, Kuchen T, Bussmann C, Straumann A. Influence of long-term treatment with topical corticosteroids on natural course of eosinophilic esophagitis and correlation between symptoms and endoscopy, histology, and blood eosinophils. Gastroenterology. 2013;1):S154.

105. Schoepfer A, Straumann A, Panczak R, Coslovsky M, Kuehni C, Bussmann C, et al. Development of a Symptom-based Activity Index for Eosinophilic Esophagitis: The EEsAI PRO Instrument. Swiss Medical Weekly. 2014;144:10S.

106. Schoepfer A, Straumann A, Panczak R, Coslovsky M, Kuehni C, Bussmann C, et al. The Eosinophilic esophagitis symptom score (EEsAI PRO Instrument) is easy to complete for Patients and shows good content validity. Swiss Medical Weekly. 2014;144:10S.

107. Schoepfer AM, Safroneeva E, Kuehni C, Zwahlen M, Schibli S, Mueller P, et al. Development of the first disease activity index for eosinophilic esophagitis: Update on the EEsAI in 2012. Swiss Medical Weekly. 2012;142:10S.

108. Seth N, Olive AP, Davis CM. Combination therapy is effective in patients with Eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2013;1):AB180.

109. Spergel JM, Andrews T, Brown-Whitehorn TF, Beausoleil JL, Liacouras CA. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Annals of Allergy, Asthma, & Immunology. 2005;95(4):336-43.

110. Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, 3rd, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. Journal of Allergy & Clinical Immunology. 2012;129(2):456-63, 63.e1-3.

111. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. Journal of Allergy & Clinical Immunology. 2006;118(6):1312-9.

112. Straumann A, Bussmann C, Conus S, Beglinger C, Simon HU. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. Journal of Allergy & Clinical Immunology. 2008;122(2):425-7.

113. Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. 2010;139(5):1526-37, 37.e1.

114. Straumann A, Conus S, Degen L, Frei C, Bussmann C, Beglinger C, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clinical Gastroenterology & Hepatology. 2011;9(5):400-9.e1.

115. Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21-30.

116. Straumann A, Hoesli S, Bussmann C, Stuck M, Perkins M, Collins LP, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013; 68(3):[375-85 pp.].

117. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2003;125(6):1660-9.

118. Stribling JT, Uram-Tuculescu C, Abu-Shukair M, Irani AM. Differential effect of swallowed inhaled corticosteroids on eosinophilic infiltration of the proximal vs the distal esophagus in eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2011;1):AB109.

119. Subbarao G, Rosenman MB, Ohnuki L, Georgelas A, Davis M, Fitzgerald JF, et al. Exploring potential noninvasive biomarkers in eosinophilic esophagitis in children. Journal of Pediatric Gastroenterology & Nutrition. 2011;53(6):651-8.

120. Syrigou E, Angelakopoulou A, Zande M, Panagiotou I, Roma E, Pitsios C. Allergy-test-driven elimination diet is useful in children with eosinophilic esophagitis, regardless of the severity of symptoms. Pediatric Allergy & Immunology. 2015;26(4):323-9.

121. Taft T, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Keefer L. Preliminary validation of a measure of adult eosinophilic esophagitis patient reported outcomes. Gastroenterology. 2011;1):S239.

122. Taft T, Kwiatek MA, Keefer L. Predictive and convergent validity of the esophageal symptom questionnaire (ESQ) for adult EoE patients. Gastroenterology. 2011;1):S241.

123. Taft TH, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Keefer L. The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. Alimentary Pharmacology & Therapeutics. 2011;34(7):790-8.

124. Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology. 2002;122(5):1216-25.

125. van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ. The Endoscopic Reference Score shows modest accuracy to predict histologic remission in adult patients with eosinophilic esophagitis. Neurogastroenterol Motil. 2016;28(11):1714-22.

126. Van Rhijn BD, Vlieg-Boerstra BJ, Versteeg SA, Akkerdaas JH, Van Ree R, Terreehorst I, et al. Evaluation of allergen-microarray-guided dietary intervention as treatment of eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 2015;136(4):1095-7e3.

127. van Rhijn BD, Warners MJ, Curvers WL, van Lent AU, Bekkali NL, Takkenberg RB, et al. Evaluating the endoscopic reference score for eosinophilic esophagitis: moderate to substantial intra- and interobserver reliability. Endoscopy. 2014;46(12):1049-55.

128. Wechsler JB, Johnson K, Amsden K, Bass LM, Prozialeck J, Cohran VC, et al. Prospective study evaluating diagnostic and post intervention endoscopic findings in children with eosinophilic esophagitis. Gastroenterology. 2015;1):S412-S3.

129. Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, Shaheen NJ, et al. Evaluation of histologic cutpoints for treatment response in eosinophilic esophagitis. Journal of Gastroenterology and Hepatology Research. 2015;4(10):1780-7.

130. Wolf WA, Jerath MR, Sperry SLW, Shaheen NJ, Dellon ES. Dietary Elimination Therapy Is an Effective Option for Adults With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology. 2014;12(8):1272-9.

| |

|Table 1. Outcome measures in published EoE Randomized-controlled trials |

|Reference |

Reference

1. Alexander JA, Jung KW, Arora AS, et al. Swallowed Fluticasone Improves Histologic but not Symptomatic Responses of Adults with Eosinophilic Esophagitis. 2012 Jul;10(7):742-749.

2. Grudell a BM, Alexander J a, Enders FB, et al. Validation of the Mayo Dysphagia Questionnaire. Dis. Esophagus 2007;20:202–5.

3. Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. [Internet]. Gastroenterology 2011;141:1593–604.

4. Flood EM, Beusterien KM, Amonkar MM, et al. Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires*. [Internet]. Curr. Med. Res. Opin. 2008;24:3369–81.

5. Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology 2014;147:324–33.

6. Peterson K a, Byrne KR, Vinson L a, et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am. J. Gastroenterol. 2013;108:759–66.

7. Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012;143:321–4.

8. Dellon ES, Katzka DA, Collins MH, et al. Oral budesonide suspension significantly improves dysphagia and esophageal eosinophilia: Results from a multicenter randomized double-blind placebo-controlled trial in adolescents and adults with eosinophilic esophagitis. Gastroenterology. 2017 Mar;152(4):776-786.

9. Dellon ES, Irani AM, Hill MR, et al. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis Aliment. Pharmacol. Ther. 2013;38:634–642.

10. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013;62:489–95.

11. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418–29.

12. Aceves SS, Bastian JF, Newbury RO, et al. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am. J. Gastroenterol. 2007;102:2271–9.

13. Ghaffari G. A randomized double blind placebo controlled crossover study of the effect of swallowed beclomethasone dipropionate on inflammatory markers in adult patients with eosinophilic esophagitis:A pilot study. Ann. Allergy, Asthma Immunol. 2012;109:A19-a20.

14. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 2015;13:66–76.

15. Kavitt RT, Ates F, Slaughter JC, et al. Dilate or medicate? A randomized, blinded, controlled trial comparing esophageal dilation to no dilation among adult patients with eosinophilic esophagitis. Gastroenterology 2014;1):S16–S17.

16. Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139:1526–37, 1537.

17. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381–91.

18. Miehlke S, Hruz P, Vieth M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016;65:390–9.

19. Moawad FJ, Veerappan GR, Dias J a, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am. J. Gastroenterol. 2013;108:366–72.

20. Peterson K a, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig. Dis. Sci. 2010;55:1313–9.

21. Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J. Allergy Clin. Immunol. 2015;135:500–507.

22. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin. Gastroenterol. Hepatol. 2008;6:165–73.

23. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2012;129:456–63, 463–3.

24. Hepner KA, Sechrest L. Confirmatory factor analysis of the Child Health Questionnaire-Parent Form 50 in a predominantly minority sample. Qual. Life Res. 2002;11:763–73.

25. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010;59:21–30.

26. Straumann A, Spichtin H, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years [Internet]. Gastroenterology 2003;125:1660–1669.

27. Straumann A, Hoesli S, Bussmann C, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013;68:375–85.

28. Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 2011;9:400–9.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download